Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

Source: 
Pharmaforum
snippet: 

Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug that only needs to be dosed by subcutaneous injection every six months, keeping it on course for regulatory filings next year.